SLQT

SELECTQUOTE INC

Financial Services | Micro Cap

-$0.48

EPS Forecast

$265.7

Revenue Forecast

The company already released most recent quarter's earnings. We will publish our AI's next quarter's forecast around 2026-12-31

SelectQuote, Inc. Q3 2026: Revenue Rises, Cash Flow Takes Center Stage, and Receivables Plateau

Ticker: NYSE: SLQT • EPS: not disclosed in the release • earnings surprise: not reported • EPS consensus: not stated • revenue forecast: full-year guidance provided • Adjusted EBITDA: disclosed for the quarter. This summary parses the SEC filing excerpt and offers context on what the numbers imply for the company and its peers.

Overview: a quarter anchored by revenue growth and cash-flow discipline

SelectQuote reported its third quarter of fiscal year 2026 with consolidated revenue of $430.9 million, up from $408.2 million a year earlier. Net income reached $40.2 million versus $26.0 million in the prior-year period, while Adjusted EBITDA came in at $44.6 million, up from $37.7 million. Notably, the company did not publish an EPS figure in the press release excerpt, leaving the market to interpret profitability through the lens of GAAP net income and non‑GAAP adjustments rather than a traditional earnings-per-share stat. The absence of an explicit EPS figure also means there is no official EPS consensus or obvious earnings surprise either from the document itself.

On the forecast side, management provided a fiscal 2026 revenue range of $1.61 billion to $1.71 billion and an Adjusted EBITDA range of $90 million to $100 million, signaling a focus on cash generation even as the business remains multi-segment and service-driven. The guidance anchors expectations for ongoing operating leverage, even as the company navigates a sizable receivables base and ongoing investments in its SelectRx and Medicare-adjacent initiatives.

Segment highlights: where the revenue comes from

The company breaks results into three operating segments, each with its own revenue and standout metrics.

Senior — Revenue: $182.9 million; Adjusted EBITDA: $58.6 million; Approved Medicare Advantage policies: 175,557.

Healthcare Services — Revenue: $199.4 million; Adjusted EBITDA: $5.3 million; SelectRx membership: 116,616.

Life — Revenue: $47.9 million; Adjusted EBITDA: $6.1 million.

The mix underscores a balanced portfolio with a large cash-generating Senior line and complementary healthcare services that include a robust SelectRx presence. The Medicare Advantage policy activity and SelectRx member base hint at growth vectors tied to policy approvals and prescription-drug servicing, respectively.

Working capital signals: receivables climb and the cash-flow narrative

Management notes the company’s receivables balance is approaching the $1 billion mark, having grown by roughly $50 million over the past year. Management also flagged a $14 million positive change in estimate related to the durability and reliability of these future cash flows. The trend line suggests that SelectQuote’s cash-generating engine remains intact, even as the accounts receivable tail continues to influence working capital dynamics.

Investors will want to watch how this receivables trajectory interacts with the company’s financing strategy and capital structure evolution, particularly given the ongoing emphasis on cash flow as a driver of value in a business that blends technology-enabled brokers with fee-based services.

Management commentary: cash flow as a strategic currency

CEO Tim Danker framed the quarter as evidence of durable profitability and cash generation, noting that the business is driven by operating execution and the leverage of the company’s information and technology advantages. He emphasized that revenue to customer acquisition cost is in the 6.7x range—a ratio he framed as a marker of the value delivered to policyholders and prescription-drug customers, even if the headline figures do not light up the blogosphere with a single “beat.”

Further, Danker signaled a continued focus on capital structure improvement and the expansion of SelectRx, framing improved cash flow as a long‑range enabler of growth rather than a one-off quarterly flourish. The narrative is less about a flashier earnings surprise and more about sustainable profitability and the ability to convert future cash flows into tangible balance-sheet strength.

Non-GAAP disclosures and what they imply for valuation

The release includes a standard reminder that certain metrics are Non-GAAP financial measures and directs readers to the accompanying discussion of these metrics. As with many tech-enabled, consumer-accessible financial-services businesses, the reliance on Adjusted EBITDA and similar non-GAAP metrics remains a core part of the narrative—used to illustrate operating performance and cash flow potential beyond GAAP earnings. For investors, that means parsing the “headline” profitability through the lens of non-GAAP adjustments, and weighing those measures against the company’s free cash flow and working-capital needs.

Takeaways for peers and the sector

What SelectQuote signals to its sector peers is a disciplined pivot toward cash-flow visibility and capital-management discipline, even as a diversified segment mix anchors growth. The sizable receivables stack could be a risk if aging accelerates or if discounting and collections pressures intensify; conversely, it could reflect a durable, service-led revenue stream backed by long-tail, recurring policy and prescription-drug relationships. The emphasis on SelectRx growth and Medicare Advantage policies also hints at regulatory and policy-driven demand that could outsize traditional marketing spend, should policy landscapes remain favorable.

For investors, the key questions will be: how durable is the current revenue mix as the company scales its non-Senior segments, and how effectively can management convert receivables into working capital that funds growth without eroding returns? The answer will shape whether SLQT is viewed more as a cash-flow machine, a growth-first bet, or a hybrid with a leaner path to margin expansion.

Conclusion: a quarter that leans on cash, not fireworks

In a climate where earnings reports often come with loud headlines and louder market reactions, SelectQuote’s Q3 2026 results read as a steadier playbook: revenue up year over year, net income higher, and EBITDA trending higher alongside a still-mazy but manageable receivables profile. The guidance suggests confidence in 2026-that-looks-roughly-the-same-but-better on a cash basis, rather than a dramatic leap in GAAP earnings. If the sector peers can replicate the balance between growth initiatives and cash-flow discipline, the next few quarters could tilt toward multiple expansion driven by improved visibility into profitability rather than sporadic earnings surprises.

Note: This summary reflects the SEC filing excerpt and accompanying press-release language. Figures are as reported for the third quarter of fiscal year 2026 unless otherwise noted.